CN103585272A - Capsule and tablet rich in SDG (secoisolariciresinol diglucoside) and bunge pine cone lignans and particularly suitable for middle-aged women to resist ageing - Google Patents
Capsule and tablet rich in SDG (secoisolariciresinol diglucoside) and bunge pine cone lignans and particularly suitable for middle-aged women to resist ageing Download PDFInfo
- Publication number
- CN103585272A CN103585272A CN201310565322.6A CN201310565322A CN103585272A CN 103585272 A CN103585272 A CN 103585272A CN 201310565322 A CN201310565322 A CN 201310565322A CN 103585272 A CN103585272 A CN 103585272A
- Authority
- CN
- China
- Prior art keywords
- sdg
- capsule
- tablet
- lignanoid
- lignans
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- SBVBJPHMDABKJV-PGCJWIIOSA-N secoisolariciresinol diglucoside Chemical compound C1=C(O)C(OC)=CC(C[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)CC=2C=C(OC)C(O)=CC=2)=C1 SBVBJPHMDABKJV-PGCJWIIOSA-N 0.000 title claims abstract description 27
- SBVBJPHMDABKJV-UHFFFAOYSA-N secoisolariciresinol diglycoside Natural products C1=C(O)C(OC)=CC(CC(COC2C(C(O)C(O)C(CO)O2)O)C(COC2C(C(O)C(O)C(CO)O2)O)CC=2C=C(OC)C(O)=CC=2)=C1 SBVBJPHMDABKJV-UHFFFAOYSA-N 0.000 title claims abstract description 27
- 239000002775 capsule Substances 0.000 title claims abstract description 14
- 230000032683 aging Effects 0.000 title abstract description 6
- 235000008331 Pinus X rigitaeda Nutrition 0.000 title abstract 3
- 235000011613 Pinus brutia Nutrition 0.000 title abstract 3
- 241000018646 Pinus brutia Species 0.000 title abstract 3
- 241000612118 Samolus valerandi Species 0.000 title abstract 3
- 229930013686 lignan Natural products 0.000 title abstract 3
- 235000009408 lignans Nutrition 0.000 title abstract 3
- 150000005692 lignans Chemical class 0.000 title abstract 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 16
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 229920002472 Starch Polymers 0.000 claims abstract description 8
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 8
- 235000019698 starch Nutrition 0.000 claims abstract description 8
- 239000008107 starch Substances 0.000 claims abstract description 8
- 108010011485 Aspartame Proteins 0.000 claims abstract description 6
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 6
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims abstract description 6
- 239000000605 aspartame Substances 0.000 claims abstract description 6
- 235000010357 aspartame Nutrition 0.000 claims abstract description 6
- 229960003438 aspartame Drugs 0.000 claims abstract description 6
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000000811 xylitol Substances 0.000 claims abstract description 6
- 235000010447 xylitol Nutrition 0.000 claims abstract description 6
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 6
- 229960002675 xylitol Drugs 0.000 claims abstract description 6
- 238000012545 processing Methods 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 7
- 238000005550 wet granulation Methods 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 230000002605 anti-dotal effect Effects 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 claims description 2
- 239000004744 fabric Substances 0.000 claims description 2
- 235000004426 flaxseed Nutrition 0.000 claims description 2
- 238000005469 granulation Methods 0.000 claims description 2
- 230000003179 granulation Effects 0.000 claims description 2
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 2
- 238000007602 hot air drying Methods 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 238000010348 incorporation Methods 0.000 claims 1
- 239000000320 mechanical mixture Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 9
- 238000002360 preparation method Methods 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 3
- 239000003075 phytoestrogen Substances 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000002245 particle Substances 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract 2
- 206010067484 Adverse reaction Diseases 0.000 abstract 1
- 230000006838 adverse reaction Effects 0.000 abstract 1
- 230000003712 anti-aging effect Effects 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 239000002994 raw material Substances 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 3
- 230000001076 estrogenic effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940057948 magnesium stearate Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 1
- 206010051131 Mastoptosis Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010067572 Oestrogenic effect Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000005186 women's health Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a capsule and tablet which are rich in SDG (secoisolariciresinol diglucoside) and bunge pine cone lignans and particularly suitable for middle-aged women to resist ageing. The preparation product comprises ingredients in percentage by weight as follows: 0%-40% of SDG, 0%-60% of bunge pine cone lignans, 20%-98% of starch, 0%-20% of xylitol, 0%-10% of aspartame and 0%-2% of magnesium stearate. When the processing and production conditions of preparations are satisfied, the ingredients are screened by sieves with 10-100 meshes respectively, weighed according to a prescription, uniformly mixed, pelletized and dried, and products with appropriate particle sizes are screened and filled into the capsule or pressed into the tablet. The preparation product has high antioxidant and anti-ageing efficacy, can serve as phytoestrogen and is particularly suitable for middle-aged women to resist ageing, and the efficacy is superior to that of a simple drug of composition; according to the composition, the usage amount of single components is relatively reduced, so that the adverse reaction caused when the single components are used alone is relieved or reduced; and the composition has the advantages of definite curative effect, non-toxic effect, convenience in taking and low price.
Description
Technical field
The invention discloses capsule and the tablet of a kind of SDGHe of being rich in Strobilus Pini lignanoid, be used in particular for the anti-senile preparation product of female middle-aged.
Background technology
People's aging is the natural law, is irresistible, but the development of modern science can delay the aging of body.At present, a large amount of achievement in research and clinical practices show, estrogen is the root of women's health.In female body, nearly all organ, tissue, cell all can be subject to estrogenic impact.The distinctive Second Characteristic of women and so-called " feminine flavour ", be all because estrogenic effect forms, because they are all estrogenic target organs.When a lot of Urban Women have arrived one's mid-30s, occur that on the face mottle, wrinkle, the colour of skin are dark and gloomy, mastoptosis, the bodily form is fat, menoxenia, the signal that health senesces just.The appearance of these old and feeble signals, relevant with factors such as women's operating pressure, stress and body constitution and diseases.Abroad.The American-European women who waits some developed countries, they are subject to the impact of these factors equally, but they focus on supplementing phytoestrogen, the arrival of delay aging, and effect is remarkable.In recent years, this kind of method was also popular in domestic, and domestic women also starts to carry out supplementing of phytoestrogen.The natural plants estrogen that secoisolariciresinol diglucoside and Strobilus Pini lignanoid come into vogue just in recent years.
The present invention adopts wet granulation technique to carry out pre-treatment to raw material, and this technology is very ripe aspect the production of pharmaceutical preparation.Its mechanism is that liquid in binding agent is by drug powder moistened surface, make powder produce gradually adhesion strength, then under the effect of liquid bridge formation and additional mechanical force, make definite shape and big or small granule, final fixed with the form of solid bridge after super-dry, after choosing grain, make the product needing.Capsule and tabletting field, in order to guarantee mobility and the stability in product processing, used for reference granulation technique, and the quality of product is improved a lot, and improved processing technique simultaneously.
Summary of the invention
The object of the invention is to the senile-resistant efficacy feature in conjunction with two kinds of raw materials of secoisolariciresinol diglucoside (SDG) and Strobilus Pini lignanoid, coordinate other batchings, developed a kind of antidotal capsule of female middle-aged and tablet of being specially adapted to.Product has adopted the technology of wet granulation, makes the even particle size of intermediate, has good mobility and stability, has therefore optimized production technology.
Be rich in the capsule of SDGHe Strobilus Pini lignanoid and tablet is raw materials used comprises: secoisolariciresinol diglucoside, pinecone extract, starch, xylitol, aspartame, magnesium stearate etc.
The ratio used of preparing burden is as follows: various batchings and ratio combine configuration according to secoisolariciresinol diglucoside (SDG) 0%-40%, the 0%-60% of Strobilus Pini lignanoid, starch 20%-98%, xylitol 0%-20%, aspartame 0%-10% and magnesium stearate 0%-2%.
The extractive of flax seed that secoisolariciresinol diglucoside in described batching (SDG) is 20-80% for HPLC detection SDG content; Strobilus Pini lignanoid is the pinecone extract that Klason method detects the content 20-98% of lignanoid.
Described capsule and tablet product adopt wet granulation technique, technological process is as follows: by all batchings 10-100 object screen cloth, mix 10-180min, using the ethanol of 10-95% as wetting agent, carry out wet granulation, under the condition of 40-60 ℃, dry 10-180min, the product of screening 10-100 order granularity, makes finished product.
Described drying mode comprises oven dry, hot air drying and boiled bed drying.
The specific embodiment
Embodiment 1
1. choose secoisolariciresinol diglucoside (SDG), Strobilus Pini lignanoid, starch and magnesium stearate, all 80 eye mesh screens of preparing burden;
2. according to secoisolariciresinol diglucoside (SDG) 35%, Strobilus Pini lignanoid 45%, starch 19.9% and magnesium stearate 0.1%, carry out raw material mixing, fully mix 30min;
3. with 80% alcoholic solution, as binding agent, the product mixing is carried out to wet granulation;
4. the chamber dryer inner drying 30min at 50 ℃ the granule making;
5. choose the granule that can cross 10 mesh sieves, fill capsule, makes capsule product;
Note: above production process is all to carry out under the good production operation rules that meet solid beverage production.
Embodiment 2
1. choose secoisolariciresinol diglucoside (SDG), Strobilus Pini lignanoid, starch, xylitol, aspartame and magnesium stearate, all 80 eye mesh screens of preparing burden;
2. according to secoisolariciresinol diglucoside (SDG) 25%, Strobilus Pini lignanoid 25%, starch 37.5%, xylitol 10% and aspartame 2%, carry out raw material mixing, fully mix 60min;
3. with 75% alcoholic solution, as binding agent, the product mixing is carried out to wet granulation;
4. the chamber dryer inner drying 30min at 60 degrees Celsius the granule making;
5. choose the granule that can cross 18 mesh sieves, add magnesium stearate 0.5% mix homogeneously;
6. sheet on demand heavily carries out tabletting, makes tablet product;
Note: above production process is all to carry out under the good production operation rules that meet solid beverage production.
Claims (4)
1. what be rich in SDGHe Strobilus Pini lignanoid is used in particular for the antidotal capsule of female middle-aged and a tablet, it is characterized in that: in product, various batchings and ratio are as follows: secoisolariciresinol diglucoside (SDG) 0%-40%, the 0%-20% of Strobilus Pini lignanoid, starch 20%-98%, xylitol 0%-20%, aspartame 0%-10% and magnesium stearate 0%-2%.
2. be rich in the capsule of SDGHe Strobilus Pini lignanoid and a processing technique for tablet, it is characterized in that: all batchings are sieved, and mix homogeneously, granulates, dry, and the product of the unified granularity of screening, makes capsule or tablet.
3. as claimed in claim 1,
(1) secoisolariciresinol diglucoside (SDG), is characterized in that: HPLC detects the extractive of flax seed that SDG content is 20-80%;
(2) Strobilus Pini lignanoid, is characterized in that: Klason method detects the pinecone extract of the content 20-98% of lignanoid.
4. as claimed in claim 2,
(1) various batchings are sieved, and it is characterized in that: various batchings can be passed through 10-100 object screen cloth;
(2) mix, it is characterized in that: hybrid mode comprises artificial mixing and mechanical mixture, incorporation time is 10min-180min;
(3) granulation mode, is characterized in that: product adopts wet granulation;
(4) granulate, it is characterized in that: the wetting agent adopting of granulating is alcoholic solution, and alcohol concentration is 10-95%;
(5) unify granularity, it is characterized in that: the size of granularity is 10-100 order;
(6) drying mode, is characterized in that: comprise oven dry, hot air drying and boiled bed drying, baking temperature is 40-60 ℃;
(7) drying time, it is characterized in that: be 10-180min drying time.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310565322.6A CN103585272A (en) | 2013-11-14 | 2013-11-14 | Capsule and tablet rich in SDG (secoisolariciresinol diglucoside) and bunge pine cone lignans and particularly suitable for middle-aged women to resist ageing |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310565322.6A CN103585272A (en) | 2013-11-14 | 2013-11-14 | Capsule and tablet rich in SDG (secoisolariciresinol diglucoside) and bunge pine cone lignans and particularly suitable for middle-aged women to resist ageing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103585272A true CN103585272A (en) | 2014-02-19 |
Family
ID=50075726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310565322.6A Pending CN103585272A (en) | 2013-11-14 | 2013-11-14 | Capsule and tablet rich in SDG (secoisolariciresinol diglucoside) and bunge pine cone lignans and particularly suitable for middle-aged women to resist ageing |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103585272A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108450879A (en) * | 2018-03-05 | 2018-08-28 | 哈尔滨天齐人类第二基因组技术开发应用科技有限责任公司 | Conversion efficiently produces mammalian lignan method in degreasing linseed organism |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1499938A (en) * | 2001-04-04 | 2004-05-26 | Use of lignans in foods |
-
2013
- 2013-11-14 CN CN201310565322.6A patent/CN103585272A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1499938A (en) * | 2001-04-04 | 2004-05-26 | Use of lignans in foods |
Non-Patent Citations (2)
| Title |
|---|
| 何泽民等: ""木脂素的生理功能研究进展"", 《安徽农业科学》 * |
| 周秋丽编著: "《现代中药基础研究与临床》", 30 June 2012, 天津科技翻译出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108450879A (en) * | 2018-03-05 | 2018-08-28 | 哈尔滨天齐人类第二基因组技术开发应用科技有限责任公司 | Conversion efficiently produces mammalian lignan method in degreasing linseed organism |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103977100B (en) | A kind of preparation method of Radix potentillae anserinae-VC compound effervescent tablet | |
| CN104996864A (en) | Making method of nutrient dendrobium candidum vermicelli | |
| CN106136245A (en) | A kind of Fructus Lycii flavone chewable tablet | |
| CN107279655B (en) | Lycium ruthenicum effervescent tablet and preparation method thereof | |
| CN106509582A (en) | Health care effervescent tablets and preparation method thereof | |
| CN101548757A (en) | Insoluble dietary fiber of raisin tree and preparing method thereof | |
| CN103504220A (en) | Green bean cake capable of clearing summer-heat | |
| CN102772440A (en) | Processing method of ultra-micro wall-breaking oral-tablet decoction pieces by traditional Chinese medicines | |
| CN104068395A (en) | Aloe and momordica grosvenori compound capsule with strong oxidation resistance | |
| CN107137373A (en) | A kind of Tea Polyphenols effervescent tablet and preparation method thereof | |
| CN102166032A (en) | Solid hawthorn beverage and preparation method thereof | |
| CN103504292A (en) | Grape seed effervescent tablet | |
| CN103585272A (en) | Capsule and tablet rich in SDG (secoisolariciresinol diglucoside) and bunge pine cone lignans and particularly suitable for middle-aged women to resist ageing | |
| CN105343027A (en) | Procyanidine effervescent tablet and preparation method thereof | |
| CN102133388B (en) | Preparation process of placebo prepared by traditional Chinese medicine | |
| CN101317890A (en) | Process for preparing capsule for urinary system lithiasis | |
| CN102772439A (en) | Processing method of ultra-micro wall-breaking capsule-preparation decoction pieces by traditional Chinese medicines | |
| CN107496477A (en) | A kind of sugar-free sanchi flower buccal tablet and its production technology | |
| CN103550332A (en) | Capsule and preparation containing rich hydroxytyrosol, lycium barbarum polysaccharide and apple polyphenol and used for protecting liver | |
| CN102217756B (en) | Epigallocatechin gallate effervescent tablet and preparation method thereof | |
| CN105341232A (en) | Compound sustained release particle tea and preparation process thereof | |
| CN103989983A (en) | Black sesame and sophora flavescens effervescent tablet and preparation method thereof | |
| CN103652559A (en) | Blood tonifying and nourishing chewable tablets and preparation method | |
| CN106974158A (en) | A kind of black fruit fructus lycii effervescent and preparation method thereof | |
| CN105125762A (en) | Vine tea chewable tablets facilitating dissolution of effective constituents and preparing method of vine tea chewable tablets |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140219 |